DEFA14A: Vaxart Urges Stockholders to Approve Reverse Stock Split to Maintain Nasdaq Listing

Vaxart is seeking stockholder approval for a reverse stock split to maintain its Nasdaq listing and proposes reducing authorized shares at a future meeting.

Summary

• Vaxart is urging stockholders to vote in favor of a reverse stock split proposal at the upcoming Annual Meeting to avoid Nasdaq delisting.
• The company has filed a supplement to its proxy statement, announcing that the board of directors approved two items contingent on the passage of Proposal #2.
• The authorized number of shares of the company's common stock would be proportionally reduced in line with the reverse stock split ratio, subject to stockholder approval at a future special meeting.
• The reverse stock split ratio will not exceed 1-for-20.
• Vaxart emphasizes that maintaining its Nasdaq listing is crucial for preserving stockholder liquidity and attracting institutional investors.
• Stockholders who have previously voted against the proposal can change their vote before the deadline of May 20, 2025, at 11:59 p.m. Eastern Time.
• Leading independent proxy advisory firms, ISS and Glass Lewis, support Proposal #2.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the need for a reverse stock split is not ideal, the company is taking proactive steps to address the issue and maintain its Nasdaq listing. The support from ISS and Glass Lewis is also a positive sign.

Positives

• Vaxart is taking proactive steps to maintain its Nasdaq listing, which is important for stockholder liquidity and institutional investment.
• The company is responsive to stockholder feedback, as evidenced by the amendments to the reverse stock split proposal.
• Support from ISS and Glass Lewis indicates that the proposal is likely in the best interest of stockholders.

Negatives

• The need for a reverse stock split suggests that Vaxart's stock price is not performing well.
• Delisting from Nasdaq could negatively impact stockholder liquidity and access to institutional investors.

Risks

• Failure to obtain stockholder approval for the reverse stock split could result in delisting from Nasdaq.
• Even with a reverse stock split, there is no guarantee that Vaxart's stock price will improve.
• The company's reliance on forward-looking statements carries inherent risks and uncertainties.

Future Outlook

The company plans to hold a future special meeting of stockholders to approve the reduction of authorized shares, contingent on the approval of the reverse stock split at the Annual Meeting.

Management Comments

• Steven Lo, President & Chief Executive Officer, stated that the amendments to the proposal directly address stockholder feedback.
• Steven Lo emphasized the importance of maintaining the Nasdaq listing for advancing Vaxart's oral pill vaccine technology.

Industry Context

Biotechnology companies, especially those in the clinical stage, often face challenges in maintaining stock prices and Nasdaq listing requirements. Reverse stock splits are a common strategy to address these issues.

Comparison to Industry Standards

• Reverse stock splits are a relatively common practice among biotech companies facing delisting threats.
• Many companies in similar situations, such as [hypothetical company A] and [hypothetical company B], have implemented reverse stock splits to regain compliance with Nasdaq listing requirements.
• The success of a reverse stock split in improving long-term stock performance varies depending on the company's underlying fundamentals and future prospects.

Stakeholder Impact

• Stockholders could experience a reduction in the number of shares they own if the reverse stock split is approved.
• Maintaining the Nasdaq listing is intended to benefit stockholders by preserving liquidity and attracting institutional investors.
• Employees' stock options and equity-based compensation will be affected by the reverse stock split.

Next Steps

• Stockholders will vote on Proposal #2 regarding the reverse stock split at the upcoming Annual Meeting.
• The board of directors will schedule a future special meeting of stockholders to approve the reduction of authorized shares, contingent on the approval of the reverse stock split.

Key Dates

Keywords

Vaxart, reverse stock split, Nasdaq, delisting, stockholder, proxy statement, VXRT, shares, listing